Perché il prezzo del titolo THE CIGNA GROUP sta salendo?
I rialzisti dicono
Specialty pharmacy growth
Analyst highlights faster adoption of biosimilars and specialty generics that is boosting specialty pharmacy volumes and can drive a rebound in adjusted earnings as PBM headwinds fade.
Capital returns and asset sale
Analyst expects substantial share repurchases funded by proceeds from the Evicore sale to materially support adjusted earnings and offset known operational headwinds.
Contract wins and execution
Analyst points to a strong selling season with multiple new Evernorth and PBM contract wins and solid client retention that should help sustain revenue growth in core businesses.
PBM transition uncertainty and costs
Analyst warns that uncertainty around the shift to the Signature rebate-free PBM model and limited disclosure of its economics could weigh on investor sentiment and valuation.
Employer coverage cuts for GLP-1 drugs
Analyst cautions that employer decisions to limit coverage of GLP-1 therapies are likely to reduce pharmacy benefit revenue and put pressure on PBM margins.
Investment and pricing pressures on profitability
Analyst highlights elevated costs from technology buildouts, contract pricing concessions, and transition-related investments that are expected to pressure near-term earnings and constrain margin recovery.
